Israel Englander’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$30.7M Sell
438,615
-580,593
-57% -$30M 0.01% 1256
2026
Q1
$51.8M Buy
1,019,208
+615,573
+153% +$28.7M 0.02% 806
2025
Q4
$11.9M Sell
403,635
-763,825
-65% -$20.8M 0.01% 2078
2025
Q3
$30.2M Buy
1,167,460
+297,968
+34% +$8.31M 0.01% 1255
2025
Q2
$24M Buy
869,492
+720,698
+484% +$19M 0.01% 1403
2025
Q1
$4.22M Sell
148,794
-980,074
-87% -$34.8M ﹤0.01% 3033
2024
Q4
$46.9M Buy
1,128,868
+978,550
+651% +$46.8M 0.02% 819
2024
Q3
$10M Buy
150,318
+101,120
+206% +$9.28M ﹤0.01% 2179
2024
Q2
$5.84M Sell
49,198
-46,690
-49% -$5.91M ﹤0.01% 2582
2024
Q1
$10.2M Buy
95,888
+33,226
+53% +$3.35M ﹤0.01% 2171
2023
Q4
$6.23M Buy
62,662
+7,601
+14% +$639K ﹤0.01% 2600
2023
Q3
$5.69M Sell
55,061
-105,902
-66% -$11.8M ﹤0.01% 2581
2023
Q2
$19.6M Buy
160,963
+41,872
+35% +$5.59M 0.01% 1415
2023
Q1
$18.3M Sell
119,091
-23,098
-16% -$3.81M 0.01% 1399
2022
Q4
$25.5M Sell
142,189
-66,123
-32% -$10.8M 0.01% 1240
2022
Q3
$24.6M Sell
208,312
-79,599
-28% -$12.1M 0.01% 1154
2022
Q2
$41.1M Buy
287,911
+158,275
+122% +$22.6M 0.03% 768
2022
Q1
$22.3M Sell
129,636
-144,081
-53% -$24.3M 0.01% 1276
2021
Q4
$69.5M Buy
273,717
+89,389
+48% +$26.1M 0.04% 544
2021
Q3
$70.9M Sell
184,328
-234,577
-56% -$86.5M 0.04% 457
2021
Q2
$98.4M Buy
418,905
+338,679
+422% +$60.5M 0.06% 307
2021
Q1
$10.5M Sell
80,226
-476,983
-86% -$69.1M 0.01% 1721
2020
Q4
$58.2M Buy
557,209
+485,385
+676% +$49.1M 0.04% 383
2020
Q3
$5.08K Sell
71,824
-476,153
-87% -$33.2M 0.01% 1829
2020
Q2
$35.2M Sell
547,977
-68,434
-11% -$3.75M 0.05% 450
2020
Q1
$18.5M Buy
+616,411
New +$14.2M 0.04% 491
2019
Q3
Sell
-97,027
Closed -$1.42M 4412
2019
Q2
$1.42M Buy
97,027
+68,323
+238% +$1.47M ﹤0.01% 2608
2019
Q1
$584K Sell
28,704
-148,536
-84% -$2.76M ﹤0.01% 3174
2018
Q4
$2.71M Buy
+177,240
New +$2.91M ﹤0.01% 2011

Other funds holding MRNA

Israel Englander's MRNA Position: Q2 2026 in Review

Israel Englander reduced its Moderna (MRNA) stake by 57% in Q2 2026, selling an estimated $30M and leaving 438,615 shares worth $30.7M. The position accounts for 0.01% of the portfolio, ranked #1256.

Israel Englander first reported a position in MRNA in Q4 2018 and has held it in 29 quarters since. The position peaked at $98.4M in Q2 2021. 775 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Israel Englander held 438,615 shares of Moderna worth $30.7M as of Q2 2026.
  • Israel Englander sold 580,593 Moderna shares in Q2 2026, an estimated $30M.
  • Moderna made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1256 holding.
  • Israel Englander first reported a position in Moderna in Q4 2018 and has held it in 29 quarters since.
  • Israel Englander's Moderna position peaked at $98.4M in Q2 2021.
  • 775 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.